MMSI Intrinsic Value Calculator – MERIT MEDICAL SYSTEMS Reports Second Quarter Earnings for FY2023
August 3, 2023
☀️Earnings Overview
MERIT MEDICAL SYSTEMS ($NASDAQ:MMSI) announced their earnings results for the second quarter of FY2023 (ending June 30th, 2023), which showed a total revenue of USD 320.1 million — an 8.5% increase year over year. The company also saw a 32.3% year-over-year increase in net income, amounting to USD 20.2 million.
Stock Price
At the open of trading, the company’s stock opened at $79.8 and closed at $81.5, representing a 1.7% increase from the previous closing price of $80.2. This success has led to an overall positive outlook for the company’s future performance. MERIT MEDICAL SYSTEMS has a long history of providing quality healthcare products and services to the global medical community. The company is committed to providing innovative products that bring value to their customers while improving patient outcomes. As such, the second quarter earnings report demonstrates the company’s commitment to continued growth and success.
As the healthcare industry continues to grow and evolve, MERIT MEDICAL SYSTEMS is well-positioned to capitalize on new opportunities. The second quarter earnings report is a testament to the company’s success so far this year and provides an optimistic outlook for the remainder of FY2023. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for MMSI. More…
| Total Revenues | Net Income | Net Margin |
| 1.2k | 89.62 | 7.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for MMSI. More…
| Operations | Investing | Financing |
| 95.33 | -191.85 | 108.19 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for MMSI. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.84k | 633.87 | 20.94 |
Key Ratios Snapshot
Some of the financial key ratios for MMSI are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.6% | 59.2% | 9.0% |
| FCF Margin | ROE | ROA |
| 3.9% | 5.7% | 3.7% |
Analysis – MMSI Intrinsic Value Calculator
GoodWhale has conducted an analysis of MERIT MEDICAL SYSTEMS’s wellbeing. Based on our proprietary Valuation Line, we have calculated the intrinsic value of MERIT MEDICAL SYSTEMS share at $68.6. However, the stock is currently traded at $81.5, which is an 18.9% overvaluation from its intrinsic value. Therefore, we conclude that the market price for MERIT MEDICAL SYSTEMS is higher than justified, and is hence considered to be a fair price. More…
Peers
The company’s products are used in a variety of medical procedures, including cardiovascular, gastrointestinal, urological, and obstetrical/gynecological procedures. The company has a strong competitive position in the medical device market, with a leading market share in many of its product categories.
However, the company faces competition from a number of well-established competitors, including Medeon Biodesign Inc, Pixium Vision SA, and AngioDynamics Inc.
– Medeon Biodesign Inc ($TPEX:6499)
Medeon Biodesign Inc is a medical device company that develops and commercializes products for the treatment of cardiovascular diseases. The company has a market cap of 4.55B and a ROE of -6.27%. Medeon Biodesign Inc’s products are used in the treatment of coronary artery disease, heart failure, and other cardiovascular conditions. The company’s products are sold in over 30 countries worldwide.
– Pixium Vision SA ($OTCPK:PXMVF)
Pixium Vision SA is a French company that designs, develops, and markets bionic vision systems to enable patients who have lost their sight to regain some level of vision. The company’s products include the PRIMA bionic vision system, which consists of an implantable microstimulator and a wearable camera and glasses, and the IRIS II bionic vision system, which consists of an implantable microstimulator and a contact lens. Pixium Vision SA’s products are intended for use in patients with retinitis pigmentosa, macular degeneration, and other degenerative eye diseases.
– AngioDynamics Inc ($NASDAQ:ANGO)
AngioDynamics Inc is a medical device company that designs, manufactures, and sells products used by interventional physicians to treat vascular diseases. The company’s products are used in a variety of procedures, including angioplasty, thrombectomy, ablation, and vascular access. AngioDynamics Inc has a market cap of 549.46M as of 2022, a Return on Equity of -5.11%. The company’s products are used in a variety of procedures, including angioplasty, thrombectomy, ablation, and vascular access. AngioDynamics Inc’s products are sold in over 50 countries worldwide.
Summary
MERIT MEDICAL SYSTEMS reported strong financial performance for the second quarter of FY2023, with total revenue of USD 320.1 million and net income of USD 20.2 million. This represents an 8.5% increase in revenue and a 32.3% increase in net income year over year. For investors, this suggests MERIT MEDICAL SYSTEMS is a strong and growing opportunity with great potential for long-term returns. The company has a solid track record, and their strong financial performance indicates that the future prospects remain positive.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
